Mucosal Delivery of Stabilized Formulations of Exendin

What is described is a pharmaceutical formulation for intranasal administration of exendin to a mammal, wherein the formulation comprises a therapeutically effective amount of an exendin, a viscosity enhancer, methyl-beta-cyclodextrin, a surfactant, tartrate buffer to control pH and a chelating agen...

Full description

Saved in:
Bibliographic Details
Main Authors QUAY STEVEN C, COSTANTINO HENRY R, LEONARD ALEXIS KAYS
Format Patent
LanguageEnglish
Published 25.12.2008
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:What is described is a pharmaceutical formulation for intranasal administration of exendin to a mammal, wherein the formulation comprises a therapeutically effective amount of an exendin, a viscosity enhancer, methyl-beta-cyclodextrin, a surfactant, tartrate buffer to control pH and a chelating agent for cations, and wherein such exendin dosage form exhibits at least 95% exenatide recovery after storage for at least 365 days at 5° C.
Bibliography:Application Number: US20060096650